S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
Log in

Natera Stock Price, Forecast & Analysis (NASDAQ:NTRA)

$38.31
-1.21 (-3.06 %)
(As of 11/14/2019 04:00 PM ET)
Today's Range
$38.21
Now: $38.31
$40.02
50-Day Range
$31.94
MA: $36.76
$39.98
52-Week Range
$11.08
Now: $38.31
$40.92
Volume336,500 shs
Average Volume681,420 shs
Market Capitalization$2.97 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.45
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRA
CUSIPN/A
Phone650-249-9090

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$257.65 million
Book Value$0.52 per share

Profitability

Net Income$-128,150,000.00

Miscellaneous

Employees975
Market Cap$2.97 billion
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive NTRA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.


Natera (NASDAQ:NTRA) Frequently Asked Questions

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

How were Natera's earnings last quarter?

Natera Inc (NASDAQ:NTRA) announced its quarterly earnings data on Wednesday, November, 6th. The medical research company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.20. The medical research company earned $77.90 million during the quarter, compared to analyst estimates of $73.97 million. Natera had a negative return on equity of 312.89% and a negative net margin of 42.45%. Natera's quarterly revenue was up 19.3% on a year-over-year basis. During the same period in the previous year, the company earned ($0.49) earnings per share. View Natera's Earnings History.

When is Natera's next earnings date?

Natera is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Natera.

What price target have analysts set for NTRA?

5 Wall Street analysts have issued 12-month target prices for Natera's shares. Their forecasts range from $32.00 to $49.00. On average, they anticipate Natera's stock price to reach $42.40 in the next year. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Natera.

What is the consensus analysts' recommendation for Natera?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.

What are Wall Street analysts saying about Natera stock?

Here are some recent quotes from research analysts about Natera stock:
  • 1. According to Zacks Investment Research, "Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. " (11/12/2019)
  • 2. Canaccord Genuity analysts commented, "We recently had the privilege of hosting Natera CEO Steve Chapman and CFO a well-attended fireside chat at the 39th in Boston. We continue to view NTRA as an undervalued cancer company trading at the multiple of an NIPT company. NTRA remains one of our favorite stocks and is one of our top picks for 2019. We reiterate our BUY rating and $38 PT. Signatera may be a game-changer in recurrence monitoring and MRD." (9/11/2019)

Has Natera been receiving favorable news coverage?

Media stories about NTRA stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Natera earned a news sentiment score of -1.4 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Natera.

Are investors shorting Natera?

Natera saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 3,260,000 shares, an increase of 15.6% from the September 30th total of 2,820,000 shares. Based on an average trading volume of 685,400 shares, the days-to-cover ratio is presently 4.8 days. Approximately 5.2% of the shares of the stock are sold short. View Natera's Current Options Chain.

Who are some of Natera's key competitors?

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Transocean (RIG), Gran Tierra Energy (GTE) and ALJ Regional (ALJJ).

Who are Natera's key executives?

Natera's management team includes the folowing people:
  • Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
  • Mr. Steve Chapman, CEO, Pres & Director (Age 40)
  • Mr. Michael Brophy, Chief Financial Officer (Age 39)
  • Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
  • Mr. Robert A. Schueren, Chief Operating Officer (Age 57)

When did Natera IPO?

(NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a number of of institutional and retail investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.59%), Columbus Circle Investors (0.54%), Tygh Capital Management Inc. (0.20%), Lisanti Capital Growth LLC (0.20%), Perkins Capital Management Inc. (0.16%) and California Public Employees Retirement System (0.15%). Company insiders that own Natera stock include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.

Which institutional investors are selling Natera stock?

NTRA stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Lisanti Capital Growth LLC, Perkins Capital Management Inc., Dupont Capital Management Corp, Essex Investment Management Co. LLC and Meeder Asset Management Inc.. Company insiders that have sold Natera company stock in the last year include Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Robert Alan Schueren and Steven Leonard Chapman. View Insider Buying and Selling for Natera.

Which institutional investors are buying Natera stock?

NTRA stock was purchased by a variety of institutional investors in the last quarter, including Columbus Circle Investors, California Public Employees Retirement System, Chartwell Investment Partners LLC, Mackay Shields LLC, Tygh Capital Management Inc., Russell Investments Group Ltd., Envestnet Asset Management Inc. and Strs Ohio. View Insider Buying and Selling for Natera.

How do I buy shares of Natera?

Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $38.31.

How big of a company is Natera?

Natera has a market capitalization of $2.97 billion and generates $257.65 million in revenue each year. The medical research company earns $-128,150,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Natera employs 975 workers across the globe.View Additional Information About Natera.

What is Natera's official website?

The official website for Natera is http://www.natera.com/.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090 or via email at [email protected]


MarketBeat Community Rating for Natera (NASDAQ NTRA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  316 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  604
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: 52- Week Highs

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel